THE BURDEN OF DEPRESSION IN JAPAN
Author(s)
Yamabe K1, Umareddy I2, Flores NM3
1Takeda Pharmaceutical Company Ltd., Tokyo, Japan, 2Kantar Health, Singapore, Singapore, 3Kantar Health, Foster City, CA, USA
OBJECTIVES: Depression is among the leading causes of disease and consequent economic burden globally due to its high prevalence.The objective of this study was to estimate the burden of depression in Japan with respect to health-related quality of life, work-related impairment, activity impairment, and healthcare resource utilization.
Conference/Value in Health Info
2016-10, ISPOR Europe 2016, Vienna, Austria
Value in Health, Vol. 19, No. 7 (November 2016)
Code
PMH33
Topic
Economic Evaluation, Patient-Centered Research
Topic Subcategory
Health State Utilities, Patient-reported Outcomes & Quality of Life Outcomes, Work & Home Productivity - Indirect Costs
Disease
Mental Health
Your browser is out-of-date
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now